Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

NCT06585488 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06585488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Terminated
Start date
December 13, 2024
Completion date
April 23, 2026
Enrollment
47 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer, advanced esophageal adenocarcinoma, advanced gastric cancer, advanced gastroesophageal junction cancer, advanced non-squamous non-small-cell lung cancer, advanced pancreatic ductal adenocarcinoma, metastatic solid tumors